$PRTA

RBC Capital has reduced its price target for Exelixis (EXEL) to $43, indicating concerns regarding the company's performance and market outlook. The downgrade suggests that analysts are apprehensive about Exelixis's growth prospects, which might influence investor sentiment negatively. This adjustment in the price target could lead to a re-evaluation of Exelixis's stock by investors and traders, possibly resulting in selling pressure. Other biotech stocks may also react to the news as it reflects broader market conditions in the sector. Overall, the sentiment around Exelixis has become bearish due to this downgrade.